The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform
Kristina Sundquist - One of the best experts on this subject based on the ideXlab platform.
-
Levothyroxine treatment is associated with an increased relative risk of overall and organ specific incident cancers - a cohort study of the Swedish population.
Cancer epidemiology, 2020Co-Authors: Per Wändell, Axel C. Carlsson, Jan Sundquist, Kristina SundquistAbstract:Abstract High thyroid hormone values have been associated with an increased risk of incident cancers, especially breast cancer but also lung cancer and any solid cancers. We explored whether there is an increased risk of overall and cause-specific cancers in those receiving levothyroxine treatment. We included all individuals ≥ 18 years in Sweden (N = 8,573,313) on January 1 2009, and identified patients with two or more dispensed prescriptions of levothyroxine 2005–2006 (n = 253,193, 3.0 %). A cancer diagnosis in the Swedish Cancer Register 2009–2015 was used as outcome. We excluded patients with a cancer diagnosis before 2005. Cox regression was used (hazard ratios, HRs, and 95 % confidence intervals, CI) with adjustments for age, socioeconomic/neighborhood factors and co-morbidities. Totally 399,751 cases of incident cancer were identified, with a slight increased overall risk associated with levothyroxine treatment for both men, adjusted HR 1.06 (95 % CI 1.03–1.10), and women, adjusted HR 1.08 (95 % CI 1.07–1.10). For men, increased risks were found for cancers of the thyroid gland and other endocrine glands. For women, increased risks were found for cancers of the breast, endometrium, other female genitals (ovaries not included), stomach, colon, liver, pancreas, urinary bladder, Skin, Leukemia, and unspecified primary tumor. Unlike men, for women, no increased risk was found for cancer of the thyroid gland. In conclusions, levothyroxine treatment was associated with an excess cancer risk, including many different types of cancer, especially among women. Our results need confirmation by other studies, but levothyroxine is recommended to be prescribed only on approved indications.
Jianxiang Wang - One of the best experts on this subject based on the ideXlab platform.
-
Chimeric antigen receptor-modified T-cell therapy for bone marrow and Skin relapse Philadelphia chromosome-like acute lymphoblastic Leukemia: A case report.
Medicine, 2020Co-Authors: Mianzeng Yang, Bingcheng Liu, Ying Wang, Yuntao Liu, X Y Gong, Benfa Gong, Min Wang, Jianxiang WangAbstract:Rationale Chimeric antigen receptor-modified T-cell (CART) therapy has revolutionized the treatment of patients with relapsed or refractory B-cell acute lymphoblastic Leukemia (ALL). However, the capacity of CART therapy has not yet been fully elucidated. Patient concerns An 18-year-old Chinese male patient presented with multiple firm masses on the Skin all over his body following regular chemotherapy. Diagnoses Bone marrow smear and Skin biopsy confirmed that it was a bone marrow and Skin relapse from the initial B-cell ALL. Interventions CD19 CART-cell therapy was performed to manage the bone marrow and Skin of the relapsed B-cell ALL. Outcomes During CART-cell therapy, cytokine release syndrome and central nervous encephalopathy occurred. Eventually, the lesions disappeared, and the bone marrow and Skin tested minimal residual disease (MRD) negative. The patient achieved complete remission (CR). Fourteen days after testing MRD negative, he received allogeneic hematopoietic stem-cell transplantation and has remained disease free to date. Lessons The CR of this patient with Leukemia cutis demonstrated that CART exhibited efficacy in this case. While further research is still required, this treatment could potentially be used as a therapy for Skin Leukemia, lymphoma, and other primary Skin cancers.
Per Wändell - One of the best experts on this subject based on the ideXlab platform.
-
Levothyroxine treatment is associated with an increased relative risk of overall and organ specific incident cancers - a cohort study of the Swedish population.
Cancer epidemiology, 2020Co-Authors: Per Wändell, Axel C. Carlsson, Jan Sundquist, Kristina SundquistAbstract:Abstract High thyroid hormone values have been associated with an increased risk of incident cancers, especially breast cancer but also lung cancer and any solid cancers. We explored whether there is an increased risk of overall and cause-specific cancers in those receiving levothyroxine treatment. We included all individuals ≥ 18 years in Sweden (N = 8,573,313) on January 1 2009, and identified patients with two or more dispensed prescriptions of levothyroxine 2005–2006 (n = 253,193, 3.0 %). A cancer diagnosis in the Swedish Cancer Register 2009–2015 was used as outcome. We excluded patients with a cancer diagnosis before 2005. Cox regression was used (hazard ratios, HRs, and 95 % confidence intervals, CI) with adjustments for age, socioeconomic/neighborhood factors and co-morbidities. Totally 399,751 cases of incident cancer were identified, with a slight increased overall risk associated with levothyroxine treatment for both men, adjusted HR 1.06 (95 % CI 1.03–1.10), and women, adjusted HR 1.08 (95 % CI 1.07–1.10). For men, increased risks were found for cancers of the thyroid gland and other endocrine glands. For women, increased risks were found for cancers of the breast, endometrium, other female genitals (ovaries not included), stomach, colon, liver, pancreas, urinary bladder, Skin, Leukemia, and unspecified primary tumor. Unlike men, for women, no increased risk was found for cancer of the thyroid gland. In conclusions, levothyroxine treatment was associated with an excess cancer risk, including many different types of cancer, especially among women. Our results need confirmation by other studies, but levothyroxine is recommended to be prescribed only on approved indications.
Mianzeng Yang - One of the best experts on this subject based on the ideXlab platform.
-
Chimeric antigen receptor-modified T-cell therapy for bone marrow and Skin relapse Philadelphia chromosome-like acute lymphoblastic Leukemia: A case report.
Medicine, 2020Co-Authors: Mianzeng Yang, Bingcheng Liu, Ying Wang, Yuntao Liu, X Y Gong, Benfa Gong, Min Wang, Jianxiang WangAbstract:Rationale Chimeric antigen receptor-modified T-cell (CART) therapy has revolutionized the treatment of patients with relapsed or refractory B-cell acute lymphoblastic Leukemia (ALL). However, the capacity of CART therapy has not yet been fully elucidated. Patient concerns An 18-year-old Chinese male patient presented with multiple firm masses on the Skin all over his body following regular chemotherapy. Diagnoses Bone marrow smear and Skin biopsy confirmed that it was a bone marrow and Skin relapse from the initial B-cell ALL. Interventions CD19 CART-cell therapy was performed to manage the bone marrow and Skin of the relapsed B-cell ALL. Outcomes During CART-cell therapy, cytokine release syndrome and central nervous encephalopathy occurred. Eventually, the lesions disappeared, and the bone marrow and Skin tested minimal residual disease (MRD) negative. The patient achieved complete remission (CR). Fourteen days after testing MRD negative, he received allogeneic hematopoietic stem-cell transplantation and has remained disease free to date. Lessons The CR of this patient with Leukemia cutis demonstrated that CART exhibited efficacy in this case. While further research is still required, this treatment could potentially be used as a therapy for Skin Leukemia, lymphoma, and other primary Skin cancers.
Jw Young - One of the best experts on this subject based on the ideXlab platform.
-
Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous Leukemia with Leukemia cutis
Bone Marrow Transplantation, 1997Co-Authors: G Michel, F Boulad, Tn Small, P Black, G Heller, H Castro-malaspina, Bh Childs, Ap Gillio, Eb Papadopoulos, Jw YoungAbstract:Leukemia cutis (LC) is a rare feature of acute myeloblastic Leukemia (AML). Little information is available regarding its prognostic influence on post-transplant outcome. In our institution, 202 patients with AML received an allogeneic HLA-identical marrow transplant from related donors between March 1982 and January 1994. Thirteen patients had prior leukemic involvement of the Skin (Leukemia cutis or LC group) while 189 patients did not (non-LC group). There was a higher incidence of patients with the M4-M5 FAB subtypes in the LC group (83%) as compared to the non-LC group (33%). In addition, the percentage of patients transplanted in relapse was also higher in the LC group (69 vs 15%). While there were no differences observed in the rates of relapse post-transplant in the LC and non-LC groups when matched for stage of disease at transplant, the sites of relapse differed markedly. Five of six relapses in the LC group involved extramedullary sites as compared to only six of 38 relapses in the non-LC group ( P = 0.002), with a 6-year probability of extramedullary relapse of 38.5% in the LC group as compared to 3.9% in the non-LC group. This increased probability of extramedullary relapse was independent of the FAB morphology (50 vs 2% for patients with the M4-M5 subtypes in the LC and the non-LC group respectively) and of disease status at the time of transplant. Moreover, only three relapses post-transplant involved the Skin, all of which were in the LC group, with a probability of Skin relapse of 23.1% in this group. Patients with AML and Leukemia cutis have a remarkable propensity to relapse in extramedullary sites following marrow transplantation. These relapses occur in the Skin as well as other organs. Further investigations are needed to understand the biological basis of this clinical feature.